Welcome to Cell & Gene Therapy

Make-in-India for next generation treatment for Cancer,

Auto-immune and Viral Infections

About Us

We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing their ability to search and destroy tumor cells.

Our Vision

To bring curative allogenic cell therapies to India & ROW at the same time as the US & Europe

Our Mission

To ensure early, affordable and quality access to curative cell therapies to patients in India & ROW

Off the shelf Allogenic Platform

Recognising the potential of cell therapy by enhancing a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients. Using synthetic biology and non-viral cell engineering, it is possible to develop a highly potent allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells.

Off the shelf Allogenic Platform

Recognising the potential of cell therapy by enhancing a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients. Using synthetic biology and non-viral cell engineering, it is possible to develop a highly potent allogeneic, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies capable of treating challenging cancers, including solid tumors, by combining new functional attributes with the inherent cancer-fighting properties of NK cells.

Our Products

CAR-NK

CRISPR

Gamma Delta T

mRNA

OUR VIRAL VECTOR PLATFORM

Platform to support broad range of virus types. GMP production services using both transient transfection and stable packaging cell-line-based processes.Support production of vectors with either adherent or suspension-based platforms.